Marksans Pharma Ltd. — Interim / Quarterly Report 2022

Dec 7, 2021

·t· Marksans Pharma Ltd.

BSELimited Corporate Relation Department Phiroze Jeejeeboi Towers, Dalal Street, Mumbai - 40000l. Scrip Code: 524404

National Stock Exchange of India Limited Listing Department Exchange Plaza, C-l, Block-G, Bandra-Kurla Complex, Bandra (EastL Mumbai - 40005l. Symbol: MARKSANS

Sub: Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith disclosures of related party transactions for the half year ended 30[th] September, 2021. The financial results for the quarter and half year ended 30[t][h] September, 2021 both standalone and consolidated were published on 10[th] November, 2021.

Yours faithfully For Marksans Pharma Limited iPaw~ Harshvardhan Panigrahi Company Secretary

Disclosure of Related Party Disclosure for the half year ended 30[th] September, 2021 [ Standalone 1

Related Party Disclosures

• (a) Related parties where control exists

  1. Marksans Pharma (UK) Limited

  2. Marksans Holdings Limited

  3. Bell, Sons and Co. (Druggists) Limited

  4. Relonchem Limited

  5. Marksans Pharma Inc.

  6. Time-Cap Laboratories Inc.

  7. Custom Coatings Inc.

  8. Marksans Realty LLC

  9. Nova Pharmaceuticals Australasia Pty Ltd

(b) Key Management Personnel (KMP)/Directors Mr. Mark Saldanha : Managing Director Mrs. Sandra Saldanha : Whole-time Director Mr. Varddhman Vikramaditya Jain : Whole-time Director Mr. Jitendra Sharma : Chief Financial Officer Mr. Harshavardhan Panigrahi : Company Secretary Mr. Abhinna Sundar Mohanty : Independent Director Mr. Digant Mahesh Parikh : Independent Director Mr. Seetharama Raju Buddharaju : Independent Director Mrs. Meena Rani Surana : Independent Director Mr. Sunny Sharma (w.eJ 11.08.2021) : Independent Director

• (c) List of related parties with whom transactions have taken place during the half year ended 30[th] September, 2021 are as follows:

==> picture [308 x 182] intentionally omitted <==

----- Start of picture text ----- Particulars 30 Sept, 2021(Amt in INR)Sale of goodsNova pharmaceuticals 37,03,32,070.10Australasia Ptv LtdBell, Sons and Co. (Druggists) 21,80,38,866.00LimitedRelonchem Limited 71,34,22,367.00Time-Cap Laboratories Inc. 145,76,87,172.00Dividend receivedMarksans Pharma (UK) Limited 9,88,55,000.00----- End of picture text -----

GuaranteeCommission
Bell,SonsandCo.(Druggists)Limited	8,786.00
Relonchem Limited	8,572.00
Time-Cap Laboratories Inc.	6,64,168.00
Rent paidMr. Mark Saldanha	53,26,668.00
Managerialremuneration
Mr. Mark Saldanha	2,05,48,853.00
Mrs. Sandra Saldanha	35,08,782.00
Mr. Varddhman VikramadityaJain	1,20,74,914.00
Mr. Jitendra Sharma	90,14,690.00
Mr. HarshavardhanPanigrahi	12,56,778.00
Mr. Abhinna Sundar Mohanty	10,000.00
Mr. Seetharama Raju Bhuddharaju	10,000.00
Mr. Digant Mahesh Parikh	50,000.00
Mrs. Meena Rani Surana	10,000.00

(d) Balances outstanding at the end of the half year ended 30th September, 2021

Particulars	30 Sept, 2021(Amt in INR)
Trade receivable
NovaPharmaceuticalsAustralasia Pty Ltd	29,44,42,598.00
Bell,SonsandCo.(Druggists)Limited	(20,71,83,904.00)
Relonchem LimitedTime-Cap Laboratories Inc.	(27,36,4 7,758.00)152,75,47,095.00
Trade payable
Bell,SonsandCo.(Druggists)Limited	38,807.33
Relonchem Limited	8,02,125.00
Time-Cap Laboratories Inc.	2,41,05,962.33

Disclosure of Related Party Transactions for the half year ended 30[th] September, 2021 [ Consolidated 1

Related Party Disclosures

• (a) Related parties where control exists

  1. Marksans Pharma (UK) Limited

  2. Marksans Holdings Limited

  3. Bell, Sons and Co. (Druggists) Limited

  4. Relonchem Limited

  5. Marksans Pharma Inc..

  6. Time-Cap Laboratories Inc.

  7. Custom Coatings Inc.

  8. Marksans Realty LLC

  9. Nova Pharmaceuticals Australasia Pty Ltd

(b) Key Management Personnel (KMP)/Directors Mr. Mark Saldanhahaa

Mr. Mark Saldanhahaa : Managing Director Mrs. Sandra Saldanha : Whole-time Director Mr. Varddhman Vikramaditya Jain : Whole-time Director Mr. Jitendra Sharma : Chief Financial Officer Mr. Harshavardhan Panigrahi : Company Secretary Mr. Abhinna Sundar Mohanty : Independent Director Mr. Digant Mahesh Parikh : Independent Director Mr. Seetharama Raju Buddharaju : Independent Director Mrs. Meena Rani Surana : Independent Director Mr. Sunny Sharma (w.e.r 11.08.2021) : Independent Director

Particulars	30 Sept, 2021(Amt in INR)
Rent paid
Mr. Mark Saldanha	53,26,668.00
Managerialremuneration
Mr. Mark SaldanhaMrs. Sandra SaldanhaMr. Varddhman VikramadityaJainMr. Jitendra SharmaMr. HarshavardhanPanigrahiMr. AbhinnaSundar MohantyMr. SeetharamaRaju BhuddharajuMr. Digant Mahesh ParikhMrs. Meena Rani Surana	2,05,48,853.0035,08,782.001,20,74,914.0090,14,690.0012,56,778.0010,000.0010,000.0050,000.0010,000.00